Table 1 Summary of IC50 values for 10 drugs derived from single-drug dose-response assays in 10 CRC PDO lines

From: A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids

Drug

Average IC50 (µM)

CRC PDO Average IC50 (µM)

Cmax (µM)

ptCRC04

ptCRC07

mCRC07

ptCRC08

mCRC08

ptCRC09

ptCRC11

mCRC11

ptCRC13

mCRC16

5-fluorouracil

8.66 ± 8.32

36.72 ± 15.1

18.54 ± 13.18

11.62 ± 4.05

69.63 ± 47.43

1.09 ± 0.23

194 ± 32.13

17.94 ± 9.58

46.51 ± 25.44

127.57 ± 24.1

53.23

426

Oxaliplatin

8.85 ± 5.9

24.55 ± 13.58

10.97 ± 1.36

2.62 ± 1.67

22.11 ± 9.78

1.04 ± 1.18

120.97 ± 32.18

10.28 ± 1.79

37.15 ± 22.62

14.26 ± 9.33

25.28

4.96

Leucovorin

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

2.86

SN-38

0.00528 ± 0.00071

0.01656 ± 0.01551

0.00514 ± 0.0026

0.008 ± 0.002

0.2806 ± 0.19554

0.0059 ± 0.0003

0.37023 ± 0.03774

0.13 ± 0.18

0.16982 ± 0.16458

0.4289 ± 0.29754

0.14204

0.143

Regorafenib

8.66 ± 4.34

7.23 ± 4.83

2.64 ± 0.28

2.24 ± 0.98

2.24 ± 0.28

5.4 ± 3.25

9.34 ± 2.89

3.78 ± 1.05

7.85 ± 3.67

6.42 ± 4.47

5.58

8.08

Pemrametostat

285.2 ± 156

214.87 ± 169.81

5.61 ± 3.22

67.99 ± 46.55

89.82 ± 53.4

42.75 ± 35.17

N.D.

N.D.

160.15 ± 98.28

N.D.

123.77

3.54

TP-064

18.06 ± 9.02

8.38 ± 3.34

3.05 ± 1.05

15.83 ± 4.13

24.02 ± 5.95

10.72 ± 0.57

22.6 ± 13.02

6.92 ± 3.18

47.15 ± 11.18

38.14 ± 5.38

19.49

–

Decitabine

2.26 ± 2.43

48.17 ± 38.73

25.98 ± 16.58

133 ± 110.65

207.93 ± 16.46

18.53 ± 25.67

149.92 ± 122.97

251.88 ± 170.47

395.33 ± 252.84

N.D.

113.62

0.323

Entinostat

2.29 ± 1.79

3.17 ± 1.43

28.7 ± 1.41

1.11 ± 0.06

1.26 ± 0.3

0.73 ± 0.31

0.73 ± 0.12

5.26 ± 2.97

3.19 ± 1.09

1.51 ± 0.24

4.80

0.19

Vorinostat

0.67 ± 0.32

1.85 ± 0.7

1.27 ± 0.23

0.998 ± 0.179

0.63 ± 0.28

1.01 ± 1.46

1.07 ± 0.35

2.75 ± 1.19

1.43 ± 0.42

0.24 ± 0.08

1.19

1.2

  1. IC50 values are represented as means ± SD (n = 3). Cmax concentrations were determined from prior pharmacokinetic studies. Cmax for TP-064 has not yet been established.
  2. N.D. not determined.